CD160 Expression in Corneal Vessels

Study Overview
=================
Brief Summary
-----------------
Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis

Detailed Description
-----------------
After informed consent, patients enrolled for corneal graft surgery at the Robert Debré University Hospital, Reims, France, will be included. Routine general and eye examination including cornea photographs will be performed. During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared for immunohistochemistry analyzes.

Official Title
-----------------
CD160 Ans Corneal Graft: Expression in Corneal Vessels

Conditions
-----------------
CD160, Corneal Graft Rejection, Angiogenesis, Lymphangiogenesis

Intervention / Treatment
-----------------
* Biological: Immunohistochemistry and clinical analyses on patients and corneas


Participation Criteria
=================
Eligibility Criteria
-----------------
inclusion criteria : 18-year-old or more patients enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France considered able to give an informed written consent exclusion criteria : none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HOSTS<br>patients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor | Biological: Immunohistochemistry and clinical analyses on patients and corneas<br>* Immunohistochemistry and clinical analyses on patients and corneas<br>|
| DONORS<br>grafts from donors that would be analyzed | Biological: Immunohistochemistry and clinical analyses on patients and corneas<br>* Immunohistochemistry and clinical analyses on patients and corneas<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Micro-vascular densities | neovascularization scores quantification of blood (anti-ERG+/anti-D2-40-) and lymphatic (anti-ERG+/anti-D2-40+) vascular structures ; Percentages of those vascular structures marked with anti-CD160 | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentages of those vascular structures marked with anti-CD160 and/or CD105 and/or aSMA |  | 1 year | 
| Evaluation of clinical blood vascular densities on photographs with help of ImageJ software |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Corneal Graft Rejection, CD160, Angiogenesis, lymphangiogenesis